This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
rsi: Archive
Down -9.57% in 4 Weeks, Here's Why Flyware (FLYW) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Flyware (FLYW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
FLYWPositive Net Change
rsi stock-price-movement
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
CLDXNegative Net Change
rsi stock-price-movement
Here's Why Steris (STE) is Poised for a Turnaround After Losing -9.06% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
STENegative Net Change
rsi stock-price-movement
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
by Zacks Equity Research
Ocular Therapeutix (OCUL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
OCULNegative Net Change
rsi stock-price-movement
Zoom Video (ZM) Loses -9.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Zoom Video (ZM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZMNegative Net Change
rsi stock-price-movement
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RNACPositive Net Change
rsi stock-price-movement
Down -24.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Health Catalyst (HCAT)
by Zacks Equity Research
Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
HCATPositive Net Change
rsi stock-price-movement
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
by Zacks Equity Research
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GRTSNo Net Change
rsi stock-price-movement
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
by Zacks Equity Research
Celldex (CLDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CLDXNegative Net Change
rsi stock-price-movement
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
by Zacks Equity Research
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
JANXNegative Net Change
rsi stock-price-movement
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
by Zacks Equity Research
Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
GNLXNegative Net Change
rsi stock-price-movement
Down -32.9% in 4 Weeks, Here's Why Workhorse (WKHS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Workhorse (WKHS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
WKHSNegative Net Change
rsi stock-price-movement
Down -13.97% in 4 Weeks, Here's Why Consolidated Water (CWCO) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Consolidated Water (CWCO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
CWCONegative Net Change
rsi stock-price-movement
M-tron Industries, Inc. (MPTI) Loses -34.77% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for M-tron Industries, Inc. (MPTI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
MPTIPositive Net Change
rsi stock-price-movement
comScore (SCOR) Loses -15.07% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for comScore (SCOR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SCORNegative Net Change
rsi stock-price-movement
Down -6.99% in 4 Weeks, Here's Why You Should You Buy the Dip in Doximity (DOCS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Doximity (DOCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
DOCSNegative Net Change
rsi stock-price-movement
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
GLPGNegative Net Change
rsi stock-price-movement
AST SpaceMobile (ASTS) Loses -33.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for AST SpaceMobile (ASTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ASTSPositive Net Change
rsi stock-price-movement
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RXRXNegative Net Change
rsi stock-price-movement
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ADVMPositive Net Change
rsi stock-price-movement
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
by Zacks Equity Research
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CRVSNegative Net Change
rsi stock-price-movement
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Aeva Technologies (AEVA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Aeva Technologies (AEVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AEVANegative Net Change
rsi stock-price-movement
Tigo Energy, Inc. (TYGO) Loses -19.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Tigo Energy, Inc. (TYGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
TYGOPositive Net Change
rsi stock-price-movement
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ADVMPositive Net Change
rsi stock-price-movement
After Plunging -13.63% in 4 Weeks, Here's Why the Trend Might Reverse for Brainsway (BWAY)
by Zacks Equity Research
Brainsway (BWAY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
BWAYPositive Net Change
rsi stock-price-movement